Clinical Data

Kailera’s three-pronged obesity shot shows promise in early trial

BioPharma Dive

As Lilly completes the pivotal program for its triple-G drug, Phase 1 data from Kailera partner Hengrui suggest their offering might spur greater weight loss.

Metabolic & GLP-1

Read full story

pharminent May 27, 2026 (Last updated: May 30, 2026)

BioPharma Dive

As Lilly completes the pivotal program for its triple-G drug, Phase 1 data from Kailera partner Hengrui suggest their offering might spur greater weight loss.

Metabolic & GLP-1

Read full story

Related Stories

ASCO: BMS hails “compelling” phase 3 celmod readout

Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peers

GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’

You May Have Missed

ASCO: BMS hails “compelling” phase 3 celmod readout

Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peers

Replimune gives cancer immunotherapy a third try after FDA leadership shakeup

FDA delays verdict on Beren’s rare disease drug by three months